PolyPid Ltd. filings document foreign private issuer disclosures for a biopharmaceutical company developing PLEX-based controlled-release therapeutics. Form 6-K reports furnish corporate updates, financial results, FDA and NDA-related disclosures for D-PLEX100, SHIELD II clinical and pharmacokinetic information, GMP inspection updates, and business-operation summaries.
The company’s regulatory record also covers capital-structure and governance matters, including ordinary-share sales agreement disclosures, legal opinions tied to share issuance, Form F-3 and Form S-8 registration statement references, shareholder meeting results, board composition, director compensation approvals, and risk and operating disclosures incorporated into its SEC registration framework.
PolyPid Ltd. director Joseph BenAmram has reported his initial derivative holdings in company stock options. The Form 3 shows three stock option grants over ordinary shares with different exercise prices and vesting schedules. One grant covers 625 underlying shares at an exercise price of $11.4000 per share, expiring on May 8, 2033, and vests quarterly until May 8, 2026. A second grant covers 6,500 underlying shares at an exercise price of $4.2400, expiring on July 2, 2034, which was fully vested as of July 2, 2025. The third grant covers 14,440 underlying shares at an exercise price of $2.6700, expiring on June 25, 2035, and vests on a quarterly basis beginning May 12, 2025 until May 12, 2029. The filing lists these as direct holdings and does not show any new purchases or sales, only existing option positions.
PolyPid Ltd. director Story Brooke reported an initial holding of stock options on Ordinary Shares. The options cover 17,456 underlying Ordinary Shares at an exercise price of $4.01 per share and expire on February 4, 2036. According to the footnote, these options were granted on February 4, 2026 and vest on a quarterly basis beginning December 11, 2025, continuing through December 11, 2029.
PolyPid Ltd. director Krinsky Itzhak filed an initial ownership report showing a mix of ordinary shares and stock options. He directly holds 833 Ordinary Shares. He also holds several stock option awards over Ordinary Shares, including 6,500 shares at an exercise price of $4.2400 expiring on July 2, 2034 and 14,440 shares at $2.6700 expiring on June 25, 2035. Additional options cover smaller amounts of shares at exercise prices of $11.4000 and $23.0700 with expiration dates between 2029 and 2033. Footnotes state that most of these options are already fully vested, while the June 25, 2025 grant vests quarterly until May 12, 2029.
PolyPid Ltd. director and Chief Executive Officer Dikla Czaczkes Akselbrad filed an initial ownership report listing her existing equity position in the company. The filing shows direct holdings of 934 Ordinary Shares and multiple stock options to buy additional Ordinary Shares at exercise prices ranging from 92.8900 down to 2.6700 per share, with expiration dates between 2026 and 2035. Several option grants are already fully vested, while others vest on a quarterly basis over future periods, indicating a mix of long-standing and more recent compensation awards rather than new market purchases or sales.
PolyPid Ltd. deputy CEO and EVP R&D Hazan Dalit Fellous has filed an initial Form 3 reporting holdings of employee stock options over the company’s ordinary shares. The filing lists multiple option grants with exercise prices ranging from 2.6700 to 92.8900 per share and expirations between 2026 and 2035.
Several grants are disclosed as fully vested based on earlier grant dates, while others vest on a quarterly schedule through dates such as May 9, 2026, August 7, 2027, May 6, 2028, and May 12, 2029. This Form 3 records existing derivative holdings and does not show any new purchases or sales.
PolyPid Ltd. provides an annual update centered on D-PLEX100, its lead local, controlled-release antibiotic for preventing surgical site infections after abdominal colorectal surgery. In the pivotal SHIELD II Phase 3 trial, D-PLEX100 plus standard care cut primary endpoint events to 10.9% versus 18.1% with standard care alone, a 40% reduction (p<0.005), and also reduced deep and superficial infections to 3.8% versus 9.5%. The company reports positive FDA pre-NDA meeting minutes and plans a rolling NDA submission beginning by the end of the first quarter of 2026, supported by Fast Track and Breakthrough Therapy designations and EMA centralized-procedure eligibility. Beyond D-PLEX100, PolyPid highlights an early long-acting GLP-1 platform for ~60-day subcutaneous release, the OncoPLEX intra-tumoral chemotherapy candidate, and a new STING-agonist collaboration, while noting it has never generated revenue and expects to need substantial additional funding as a development-stage biopharmaceutical company.
PolyPid Ltd. shareholder filing shows a concentrated institutional position with warrant overhang. Rosalind Advisors Inc., Rosalind Master Fund L.P., and portfolio managers Steven Salamon and Gilad Aharon report beneficial ownership tied to 5,483,443 Common Shares, representing 9.9% of the class based on 18,204,002 shares outstanding as of December 31, 2025.
The filing explains that this figure includes 696,556 Common Shares plus 4,786,887 shares issuable upon warrant exercise. Because the warrants contain a 9.99% beneficial ownership blocker, the reporting persons state they could not exercise the warrants as of the event date and that the advisor and Mr. Salamon disclaim beneficial ownership of shares held by the fund.
PolyPid Ltd. reported wider losses for 2025 while advancing its lead drug D-PLEX₁₀₀ toward potential commercialization. Net loss for 2025 was $34.2 million, compared with $29.0 million in 2024, driven mainly by higher research and development and general and administrative expenses.
Cash and cash equivalents were $6.4 million at December 31, 2025, with short-term deposits of $6.5 million, bringing total current assets to $15.2 million. Shareholders’ equity increased to $11.0 million from $7.7 million, reflecting additional paid-in capital.
The company highlighted successful completion of its Phase 3 SHIELD II trial for D-PLEX₁₀₀, positive FDA pre-NDA feedback supporting a rolling NDA review, and advanced-stage U.S. commercial partnership discussions. PolyPid stated it believes 2026 could mark a transition from late-stage development to full commercial execution.
PolyPid Ltd. held an Extraordinary General Meeting of Shareholders on February 4, 2026, where a quorum was present and shareholders approved Proposal No. 1 as originally proposed. The specific substance of the proposal is not described in this excerpt.
The report states that this 6-K is incorporated by reference into several existing Form F-3 and Form S-8 registration statements, meaning those securities registration documents now also include this shareholder meeting outcome as part of their disclosure record.
PolyPid Ltd. received an amended Schedule 13G showing that investment manager AIGH Capital Management LLC and Orin Hirschman beneficially own 1,793,117 ordinary shares, representing 9.8% of the class. They report sole voting and dispositive power over these shares.
The filing notes that this ownership percentage excludes 2,395,268 common shares issuable upon exercise of warrants that are not currently exercisable due to beneficial ownership limits, and 549,141 shares held in abeyance. The holders state the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of PolyPid.